All In Biotech

Drug Trial Radar · NCT05792761

A Study on Antiviral Treatment of Chronic Hepatitis B in Children

A Study on Antiviral Treatment of Chronic Hepatitis B in Children (Sprout Project)

Last checked: Nov 20, 2026Latest source record: Mar 31, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

1,900

Planned (sponsor's estimate)

Start

May 6, 2021

Primary completion

Dec 31, 2025

Study completion Dec 31, 2025

Sponsor

Lead sponsor
Fang WangAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 31, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 3 years, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

There are nearly 2 million HBsAg-positive children who are in urgent need of professional diagnosis and treatment in China. Chronic hepatitis B (CHB) is the leading cause of childhood liver disease. After infected with HBV virus, some children will develop disease progression, and some even develop cirrhosis and/or liver cancer. In pediatric liver cancer cases, up to 34% \~ 95% are caused by HBV infection. Although two major classes of drugs have been approved for the treatment of chronic hepatitis B in adults, and there are multiple guidelines worldwide for the management of HBV infection in adults, there is lack of guidelines specifically for the management of children with HBV infection. In addition, the treatment of chronic hepatitis B in children faced great difficulties due to the lack of evidence-based medical evidence for antiviral treatment of chronic hepatitis B in children and fewer drugs approved for anti-HBV treatment in children. The timing of treatment, medications, and clinical management strategies are all controversial. This study ( Sprout project),is a multicenter, prospective, cohort study in China, aiming to explore and optimize the antiviral treatment regimen for children with HBV infection, to provide evidence-based medical for antiviral treatment, and to provide basis evidence for the standardized management of children infection with HBV in China. The study is expected to enroll 1900 pediatric patients with HBV infection, and patient will received one of the three following treatment Strategies: nucleoside monotherapy, peginterferon α- combined with nucleoside therapy, or peginterferon α-pulse therapy combined with nucleoside therapy, according to their illness state and desire, and the safety and efficacy will be evaluated.

Conditions

  • Chronic HBV Infection

Interventions

  • Peginterferon alfa-2b combined and ETVDrug

    Child patients are assigned to one of the 3 treatment regimens according to their illness state and treatment desire of their parents/guardians, and the number of patients in each group is expected to limited to 300. 1. NA monotherapy group : received entecavir (ETV) for 96 weeks. 2. Combination therapy group: received peginterferon alfa-2b combined with ETV for 96 weeks. 3. Pulse therapy group :received peginterferon alfa-2b pulse treatment combined with ETV for 144 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical cure rate.Time frame: 24 weeks after completing treatment.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shenzhen Third People Hospital

    Shenzhen, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.